A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Lawrence FongMichael J MorrisA Oliver SartorCelestia S HiganoLance PagliaroAjjai AlvaLeonard J ApplemanWinston TanUlka VaishampayanRaphaelle PorcuDarren TayamaEdward E KadelKobe C YuenAsim DatyeAndrew J ArmstrongDaniel P PetrylakPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This phase Ib study demonstrated that atezolizumab + radium-223, regardless of administration schedule, had greater toxicity than either drug alone, with no clear evidence of additional clinical benefit for patients with mCRPC and bone and lymph node and/or visceral metastases.